Risk-Sharing Arrangements That Link Payment For Drugs To Health Outcomes Are Proving Hard To Implement

• DOI: 10.1377/hlthaff.2010.1147
• Publication Date: 2011-12-06T07:53:14Z
• Authors: Peter J. Neumann; James D. Chambers; Françoise Simon; Lisa M. Meckley
• Keywords: Cost sharing

Risk-sharing agreements, under which payers and pharmaceutical manufacturers agree to link payment for drugs health outcomes achieved, rather than the volume of products used, offer an appealing model pharmaceuticals. Although such agreements have been widely touted, experience date mainly demonstrates how hard they are implement. Barriers include high implementation costs, measurement challenges, absence a suitable data infrastructure. arrangements could gain traction in United States as product acquire with concept techniques information systems improve. For foreseeable future, likely remain exception drug companies pursue models unconnected collection or performance assessment.